

REVIEW

Open Access



# The impact of dietary interventions on cardiometabolic health

Erind Gjermani<sup>1\*</sup>, Raluca Fiebiger<sup>1</sup>, Linnaeus Bundalian<sup>2</sup>, Antje Garten<sup>3</sup>, Torsten Schöneberg<sup>4,5</sup>, Diana Le Duc<sup>2,6,7†</sup> and Matthias Blüher<sup>8†</sup>

## Abstract

Obesity and cardiometabolic diseases are leading causes of morbidity and mortality among adults worldwide. These conditions significantly contribute to and exacerbate other major causes of illness and death, including cancer, neurodegenerative diseases, and chronic kidney disease. The growing burden of these diseases has increased the interest of modern medicine in understanding metabolic processes and health, with diet emerging as a pivotal modifiable factor, alongside physical inactivity and smoking. In this review, we discuss the pathophysiological and evolutionary foundations of metabolic processes that may link “unhealthy” nutrition to obesity and cardiometabolic diseases and review the current literature to assess the effects of various diet interventions and patterns on cardiometabolic parameters. Special emphasis is placed on summarizing the latest, albeit partially contradictory, evidence to offer balanced dietary recommendations with the ultimate aim to improve cardiometabolic health.

## Background

Cardiometabolic diseases (CMD) are closely linked to dietary habits and obesity, currently ranking as the leading causes of morbidity and mortality among adults worldwide [1]. The pandemic proportions of this disease cluster result not only in adverse health outcomes but also in staggering economic costs that place immense strain on healthcare budgets [2, 3]. Cardiovascular diseases (CVD), the primary contributors to global mortality, are at least theoretically preventable through effective management of behavioral and environmental risk factors. Among these, an unhealthy diet is the most significant behavioral risk factor, followed by physical inactivity and smoking [4, 5]. Furthermore, CMD substantially contribute to other major causes of global morbidity and mortality [6, 7], including cancer [7], dementia and neurodegenerative diseases [8], type 2 diabetes mellitus (T2DM) [9], and chronic kidney disease [10].

Metabolism—the process that makes the energy from food accessible for sustaining life—has gained increasing

<sup>†</sup>Diana Le Duc and Matthias Blüher contributed equally to this work.

\*Correspondence:

Erind Gjermani

erind.gjermani@median-kliniken.de

<sup>1</sup>Department of Cardiology, Median Center for Rehabilitation Schmannewitz, 04774 Dahlen, Germany

<sup>2</sup>Institute of Human Genetics, University Medical Center Leipzig, 04103 Leipzig, Germany

<sup>3</sup>Pediatric Research Center, University Hospital for Children and Adolescents, Leipzig University, 04103 Leipzig, Germany

<sup>4</sup>Rudolf Schönheimer Institute of Biochemistry, Molecular Biochemistry, Medical Faculty, University of Leipzig, Leipzig, Germany

<sup>5</sup>School of Medicine, University of Global Health Equity, Kigali, Rwanda

<sup>6</sup>Department of Genetics, Center for Diagnostics at Chemnitz Clinics, 09116 Chemnitz, Germany

<sup>7</sup>Department of Evolutionary Genetics, Max Planck Institute for Evolutionary Anthropology, 04103 Leipzig, Germany

<sup>8</sup>Helmholtz Institute for Metabolic, Obesity and Vascular Research (HIMAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, 04103 Leipzig, Germany



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.


attention in modern medicine due to its central role in chronic diseases, as well as its relevance to sports medicine and performance [11]. This growing interest stems from the recognition that metabolic processes not only regulate energy balance, but also influence inflammation, immune function, cellular health, and physical performance [11]. Understanding how dietary components impact metabolic pathways could unlock new prevention and treatment strategies for CMD (Fig. 1).

The evaluation of metabolic flexibility, insulin sensitivity, and metabolic regulation has also become an area of increasing interest [12, 13]. Recently, a novel multimarker indicative of metabolic vulnerability (i.e. six serum biomarkers including GlycA, small HDL, valine, leucine, isoleucine, and citrate concentrations) demonstrated remarkable accuracy in predicting all-cause mortality, particularly in patients with CVD [14–16]. The assessment of metabolic health and performance, through direct and indirect measures of mitochondrial function and metabolic flexibility, is widely utilized for evaluating sports performance, fitness levels, and CMD status. However, these methods are often too invasive


and complex for routine use in clinical settings [11, 17]. Fortunately, more accessible biomarkers, discussed in the following paragraph, offer reliable assessments of cardiometabolic health (CMH) [17–19].

#### Biomarkers of cardiometabolic health

CMH refers to the health of the cardiovascular and metabolic systems. It is influenced by multiple risk factors that collectively determine the likelihood of developing CVD, T2DM, and other related conditions. A practical evaluation of CMH can be achieved by assessing adiposity, blood glucose levels, blood lipid profiles, blood pressure, and the presence or absence of clinical CVD [18, 19]. Skeletal muscle plays a central role in energy metabolism, as approximately 80% of postprandial carbohydrate oxidation occurs in skeletal muscle [11, 20–22]. Insulin resistance in skeletal muscle can emerge decades before the onset of  $\beta$ -cell failure [11, 20–22]. Chronic positive energy balance tends to elevate glucose levels, prompting increased insulin production. Hyperinsulinemia suppresses hepatic glucose production and shifts liver metabolism toward the conversion of carbohydrates into



**Fig. 1** Central illustration. General dietary recommendations for cardiometabolic health. Visual representation of common foods and the level of general consensus regarding the strength of evidence (foods in the upper part have wide consensus), as well as the general recommendations (foods on the right should be emphasized in the diet)



**Fig. 2** Pathophysiological background of the clinical biomarkers (adapted from ref [20]). During excess calorie intake, de novo lipogenesis processes carbohydrates that cannot be stored as glycogen, promoting fat accumulation in the liver. Because this process is stimulated by insulin, individuals with some degree of insulin resistance (determined by genetic and lifestyle factors) accumulate liver fat more quickly due to higher insulin concentrations. Increased liver fat further exacerbates resistance to the suppression of hepatic glucose production by insulin. A small increase in plasma glucose triggers increased insulin secretion to maintain euglycemia. This resulting hyperinsulinemia further enhances the conversion of excess calories into liver fat, creating a vicious cycle. Fatty liver leads to an increased export of VLDLs into the circulation, which promotes fat delivery to all tissues, including the pancreas. Moreover, high levels of VLDL, in concert with increased CETP activity, result in the enrichment of LDL and HDL with triacylglycerols, while depleting their cholesterol content. This leads to the typical lipid triad: high triacylglycerols, low HDL cholesterol, and small LDL particles. Excess fatty acids in the pancreatic islets can impair insulin secretion in response to ingested food, leading to postprandial hyperglycemia. The hyperglycemia further increases insulin secretion, which consequently elevates hepatic lipogenesis, speeding up the liver cycle and driving the pancreas cycle. Eventually, the inhibitory effects of fatty acids and glucose on the islets reach a threshold, triggering  $\beta$ -cell failure and a fairly sudden onset of clinical diabetes. Adapted from ref. [21], with permission from Elsevier

fat [23]. This results in increased hepatic lipid production (e.g., triacylglycerols, commonly called triglycerides), fat accumulation in the liver, and ultimately the development of fatty liver and hepatic insulin resistance (Fig. 2).

The worsening of insulin resistance further escalates insulin production and enhances carbohydrate-to-lipid conversion in the liver, initiating a vicious cycle. Excess fat in the liver can lead to increased lipid export throughout the body, including deposition in abdominal organs—a hallmark of metabolic dysfunction—once subcutaneous fat storage capacity is exceeded. Pancreatic fat accumulation may impair insulin production, eventually leading to T2DM in susceptible individuals.

In this state, elevated cholesteryl ester transfer protein (CETP) activity enriches low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particles with triacylglycerol [24] while depleting their cholesterol content [25]. Hepatic lipase, upregulated by hyperglycemia [24, 26] and exhibiting increased activity in insulin-resistant states [27], rapidly metabolizes triacylglycerol-rich HDL

and LDL. This process forms small HDL particles, which are cleared more quickly, and small LDL particles, which are highly atherogenic. This contributes to the characteristic lipid triad of insulin resistance: (1) elevated plasma triacylglycerols, (2) reduced HDL cholesterol levels, and (3) the presence of highly atherogenic small LDL particles. This triad is a strong predictor of poor metabolic health.

On the other hand, improving metabolic health through a healthy lifestyle has proven highly effective in reducing CVD mortality. A striking example is the community-wide intervention in North Karelia, Finland. In the late 1960s, men in North Karelia had the highest CVD mortality rate in the world. Through comprehensive national policies and health promotion initiatives across Finland, the population achieved significant reductions in cholesterol levels, blood pressure, and smoking rates. Over 35 years, age-adjusted coronary heart disease (CHD) mortality rates decreased by 85% in North Karelia and by 80% nationwide among men aged 35–64 years

[28–30]. These findings underscore that dietary and lifestyle interventions can yield substantial improvements in CMH.

### Evolutionary insights and cardiometabolic health

Medicine in the light of evolution provides a valuable framework for understanding human health and disease by applying principles of evolutionary biology. The mismatch theory suggests that many modern diseases arise because human bodies are adapted to past environments, not the rapidly changing conditions of contemporary life. Our ancestors evolved to thrive on diets, activity levels, and stressors vastly different from today's fast-paced, sedentary lifestyle dominated by processed foods. This mismatch helps explain the rise in conditions like obesity, T2DM, and CVD, as our evolutionary adaptations are poorly suited to modern environments [31, 32]. For instance, the “thrifty genotype” hypothesis posits that traits evolved to support survival during periods of food scarcity now predispose individuals to obesity and related metabolic conditions in today's environment of caloric abundance [32]. Inflammation in CVD may also have evolutionary roots. High infectious burdens in ancestral populations likely selected for strong inflammatory responses, but in modern contexts, these pro-inflammatory genes may contribute to chronic diseases like obesity and CVD. Diet, particularly the consumption of highly processed foods rich in refined sugars, is a major driver of inflammation today. Insights into ancestral diets, enabled by next-generation sequencing, proteomics, and isotope analysis, are critical to understanding these evolutionary dynamics.

Diet has long been proposed as a key factor in hominin evolution, particularly in brain size expansion. Findings from a 3.5-million-year-old *Australopithecus* site suggest that these hominins had herbivore-like diets, distinct from carnivores, indicating that meat consumption was not a driving factor in the evolution of larger brains [33]. Dental calculus, a mineralized form of dental plaque, offers a direct window into ancient diets [34]. For instance, studies have shown that Neanderthals likely consumed roots, bulbs, and other plant materials, particularly during cooler periods when animal resources may have been less accessible [35, 36]. The analysis of dental calculus from Neanderthal remains has identified starch grains and phytoliths, which suggest a significant plant component in their diet, alongside evidence of meat consumption [35, 37]. However, alternative theories have challenged this view. Bone collagen isotope studies have significantly advanced understanding of Neanderthal diets, consistently showing exceptionally high nitrogen isotope ratios. The findings reinforce Neanderthals' role as successful top-level carnivores, even after modern humans arrived in Europe. High [15] N values in bone collagen are explained solely by mammal meat consumption,

supported by archeological evidence, without requiring alternative explanations such as food processing (fermented food, cooking), specific prey types (mammoth or young mammals), or additional protein sources like fish or mushrooms [38].

Fermented foods contain bacteria-derived D-amino acids and their metabolites, which can regulate human immune functions and energy homeostasis through hydroxycarboxylic acid receptors (HCARs). While most mammals have two HCARs (HCAR1 and HCAR2), humans and other hominids possess a third receptor, HCAR3. Evolutionary and functional evidence suggests that HCAR3 evolved in hominids as a signaling system for bacteria-derived D-amino acids and their metabolites. As HCAR3 is expressed in monocytes and adipocytes it has been speculated that aromatic D-amino acids and their derivatives from fermented fruits act as signals to attract immune cells to the gut and suppress fat breakdown in adipose tissue [39].

In modern humans, dental calculus analysis has similarly revealed a complex dietary profile. For example, Warinner et al. demonstrated that ancient human dental calculus contains evidence of milk consumption, indicating that dairy products were part of the diet at least in certain populations [34]. Furthermore, fossils from Fuyan Cave, South China, dated to about 80,000 years ago, suggest that early modern humans also engaged in diverse foraging strategies that included both cultivated and wild plant species [40]. The comparative analysis of ancient and modern dental calculus can reflect dietary changes over time. For instance, metaproteomic data from 100 archaeological dental calculus samples ranging from the Iron Age to the post-medieval period (eighth century BC to nineteenth century AD) in England detect proteomic evidence of cereals and plant products [41]. Moreover, studies have shown that the microbial profiles of dental calculus differ markedly from those of dental plaque, suggesting that dietary habits have evolved alongside changes in oral microbiomes [42, 43].

While we can gain insight into the composition of diets by examining fossils and dental calculus, the lack of information on their cardiovascular fitness prevents us from correlating nutrition with cardiovascular outcome. To this end, communities of hunter–gatherers, that are currently living in environments closer to the ancestral one, are an important mirror on how nutrition and lifestyle in general impact cardiovascular health.

Modern hunter–gatherer communities, such as the Hadza of Tanzania, provide valuable insights into ancestral nutrition and lifestyle. The Hadza's diet, rich in unprocessed, foraged foods like fruits, vegetables, tubers, and wild game, combined with high physical activity, results in exceptional cardiovascular fitness. They exhibit low rates of obesity, hypertension, and other metabolic



conditions, even in older age [44, 45]. The Mediterranean diet, which shares similarities with the traditional diet of the Hadza has been extensively studied for its cardiometabolic benefits [46–50].

The evolutionary perspective on diet emphasizes the mismatch between modern lifestyles and ancestral adaptations, highlighting the need for dietary patterns that align with our biological heritage. By drawing lessons from early hominins, Neandertals, and contemporary hunter–gatherer populations, we can better understand the role of diet in preventing CMD.

### **The role of macronutrient quality and quantity**

Carbohydrates, fats, and proteins in the diet serve as chemical building blocks and energy sources for various bodily functions. If not immediately utilized, they are stored for future use. Maintaining a stable body weight requires balancing energy intake with energy expenditure. When energy intake consistently exceeds expenditure, the excess energy is predominantly stored as fat, leading to an increase in body weight [51]. While the quantity of macronutrients in the diet offers valuable information, equally important is food quality and the complex interplay of foods and dietary patterns, on long-term weight control and metabolic health (Central illustration).

### **Dietary carbohydrates**

Foods containing carbohydrates consist principally of sugars, starches, and dietary fiber. Carbohydrates provide the main energy source for people worldwide. Upon consumption, many carbohydrates are broken down into glucose, galactose and fructose, which are either acutely utilized or transformed into glucose, stored as glycogen in the liver and muscles for later use. Other monosaccharides, such as mannose or ribose, do play a role in metabolic processes (e.g., nucleotide synthesis), but they are not directly used as primary energy sources. The acceptable macronutrient distribution range for carbohydrates is 45–65% of total daily caloric intake [52], but healthy dietary patterns can be outside this range [49]. The role of mono- and disaccharides (simple sugars) and refined grains as a determinant of adverse health outcomes has been clarified, and clear guidelines relating to their restriction issued [53–56].

Across different foods and beverages, those high in simple sugars and refined grains most strongly associate with long-term weight gain [57, 58] and T2DM [59]. The evidence is especially strong for sugary beverages [58–60]. Simple sugars and refined grains are commonly found in white bread, white rice, white potatoes, refined pastas, chips, sugary beverages, candy, and many bakery products [58, 61]. Conversely, interventional trials show weight loss and improved glycaemia on low-carbohydrate

diets [62, 63]; these evidence provides strong arguments that simple sugars should be avoided to optimize weight and metabolic health.

Dietary fibers are mainly composed of non-starch polysaccharides (e.g., cellulose, hemicellulose, pectins) and non-carbohydrate components (e.g., lignin, suberin, cutin). While fibers are not digested or absorbed by the small intestine, they have crucial roles in improving gut function and supporting the microbiome and are associated with multiple health benefits [64]. Credit for the dietary fiber hypothesis is given largely to Denis Burkitt, who had more than 50 years observed that diets low in fiber increase the risk of CMD, dental caries, and large bowel conditions such as cancer, appendicitis and diverticulosis [65]. Today nutrition guidelines encourage increased consumption of vegetables, fruit, and whole grains [53–56]. Diets rich in whole grains show a strong association with lower risks of most CMD. Risk reduction was greatest when daily intake of dietary fiber was between 25 and 29 g while dose–response curves suggested that higher intakes could confer even greater benefit. Findings from prospective studies and clinical trials associated with relatively high intakes of dietary fiber and whole grains were complementary, and striking dose–response evidence indicates that the relationships to several non-communicable diseases could be causal [64].

### **Dietary fats**

Dietary fats encompass a highly diverse range of compounds with complex effects on cell physiology, gene expression, and metabolites [66]. They can have vastly different health effects depending on its source (e.g., harmful impact of trans-fats vs beneficial properties of avocado) influenced by accompanying nutrients, molecular lipid structures, and metabolic processing. Reflecting this complexity, merely considering total quantity of dietary fat consumption is not consistently linked to CMD risk across wide ranges (~20–40%) of total daily caloric intake [61, 66].

For decades, a low-fat diet was recommended for weight loss and reducing obesity. However, findings from randomized trials have not consistently demonstrated that lowering total fat intake leads to long-term weight loss compared to other dietary interventions [63, 67, 68]. Accordingly, many organizations have concluded that evidence no longer supports an upper limit on total fat consumption [53, 54, 56, 63, 69, 70], except for the World Health Organization, which continues to recommend limiting dietary fat intake to less than 30% [71]. There is, however, consensus among health organizations advocating for the reduction of saturated fatty acids (SFA)—commonly found in animal products and tropical oils (e.g., palm oil, coconut oil, shea butter)—and replacing them with healthy fats, primarily from plant-based foods rich

in mono- and polyunsaturated fatty acids (PUFA). Examples include nuts, seeds, and non-hydrogenated vegetable oils. A recent Cochrane review confirmed that reducing saturated fat intake can decrease cardiovascular event risk by 17%. The review also found that replacing SFAs with PUFAs offers greater cardiovascular protection than replacing them with carbohydrates [72]. Another prospective cohort study with up to 45 years of follow-up, involving nearly 80,000 participants, showed that higher SFA intake was strongly associated with increased total and CVD mortality. Conversely, theoretical substitution of SFAs with carbohydrates or monounsaturated fatty acids (MUFA) was linked to a lower risk [73].

In contrast to SFAs, unsaturated fats improve glycaemic control, reduce insulin resistance, and lower T2DM risk [49, 66, 74]. While the cardiometabolic benefits of PUFAs are well-established, particularly for omega-3 PUFAs, some scientists argue that omega-6 PUFAs may be harmful [75]. This concern centers on the conversion of linoleic acid to arachidonic acid, a precursor to pro-inflammatory and thrombogenic compounds, which may negatively affect glucose metabolism, weight regulation, and eating behavior [75, 76]. However, a pooled analysis of individual-level data from 20 prospective cohort studies across 10 countries found that linoleic acid provides long-term benefits for T2DM prevention, and arachidonic acid was not associated with harm [76].

Dairy products, including milk, cheese, and yogurt, are notable sources of nutrients and dietary fat. High-fat dairy products have historically been criticized for their saturated fat content and potential CVD risk [77]. However, recent studies suggest a more complex relationship. A systematic review by Giosuè et al. found that moderate dairy consumption does not adversely affect cardiovascular health [77]. While very high milk intake (>1000 g/day) was linked to increased CVD risk, moderate consumption of fermented milk, butter, and cheese was associated with reduced risk. Cream showed no significant association [78]. Yogurt, in particular, has been consistently linked to lower long-term weight gain [61] and reductions in inflammation [79]. Nonetheless, the evidence surrounding dairy fat and CVD remains mixed, highlighting the need for further research to elucidate underlying mechanisms and achieve consensus.

Similarly, eggs are a topic of debate regarding their cardiovascular impact. Eggs are rich in phospholipids and cholesterol. A study by Dehghan et al. involving 177,000 participants from 50 countries found no significant effect of egg consumption on blood lipid levels or CVD risk [80]. Additionally, a randomized clinical trial by Gálvis et al. demonstrated that consuming two eggs daily did not adversely affect key CVD biomarkers [81]. However, egg yolk phosphatidylcholine has been linked to increased trimethylamine-N-oxide levels, a compound associated

with higher CVD risk [81]. More clinical studies with robust patient stratification are needed to clarify the role of eggs in cardiovascular health.

In conclusion, while saturated fats should be limited, emerging evidence suggests that dietary cholesterol, particularly from sources like eggs, may not have the harmful effects previously assumed, especially when consumed in moderation. Current dietary recommendations are shifting from focusing on isolated macronutrients to emphasizing overall dietary patterns, particularly plant-based diets rich in unsaturated fats, which have been associated with improved lipid profiles and reduced blood pressure.

### Dietary proteins

Dietary protein plays a central role in human health, influencing various physiological processes and health outcomes. Proteins are composed of amino acids, which are essential for synthesizing new proteins and fulfilling multiple metabolic functions. Numerous studies highlight the importance of dietary protein in regulating metabolic pathways, including those related to muscle synthesis, inflammation, and satiety. These effects are mediated primarily through signaling pathways involving glucagon-like peptide 1 (GLP-1), peptide YY (PYY), insulin, and leucine-induced activation of mTORC1, which stimulates skeletal muscle protein synthesis following protein-containing meals [82].

The Recommended Dietary Allowance (RDA) for adults is 0.8 g of protein per kilogram of body weight per day [52]. However, recent research suggests that higher protein intake is associated with various health benefits, including improved muscle mass and strength, particularly in older adults. A meta-analysis of 49 studies found that increasing dietary protein intake to up to 1.6 g/kg/day, combined with strength training, significantly improves muscle mass and strength compared to strength training alone in generally healthy, middle-aged, and older populations [83]. Another meta-analysis of 17 randomized controlled trials (RCTs) confirmed these findings, showing that protein supplementation combined with resistance training can mitigate aging-related declines in muscle mass and strength in older individuals [84].

On the other hand, high protein intake has been linked to a modestly elevated risk of T2DM [85, 86]. Animal studies have demonstrated that protein restriction, independent of calorie intake, can extend lifespan in mice and improve the health of young and middle-aged rodents, with potential implications for humans [87]. In non-restrictive feeding strategies, diets with increased protein levels increase growth hormone (GH) signaling and insulin-like growth factor 1 (IGF-1) levels which may shorten rodent lifespans by activating a pro-aging axis [88]. Some human and animal studies suggest that a low-protein diet

during middle age may help prevent cancer and improve overall mortality, potentially through the regulation of circulating IGF-1 and insulin levels [89].

The source of dietary protein—whether from animal or plant origins—also appears to have significant health implications, as different protein sources elicit distinct metabolic responses. The amino acid profiles of meat, eggs, and dairy are more closely aligned with human requirements than those of plant foods. Thus, in conditions of food scarcity, it may be easier to achieve protein adequacy through animal-based foods. However, contrary to common misconceptions, all plant foods contain all essential proteinogenic amino acids [90]. For individuals with access to a reasonably diverse diet, daily protein requirements can be easily met [90]. Mixed diets containing 90% of protein from a variety of plant foods and only 10% from animal sources can meet protein needs similarly to typical Western diets, which are significantly higher in animal protein [90, 91]. High intake of animal protein, particularly from processed meat, has been associated with an increased risk of T2DM [92], whereas this risk does not appear to extend to plant proteins [85, 86]. In fact, higher plant protein intake may even improve metabolic health [93]. Current evidence suggests avoiding processed meats and limiting unprocessed red meats and poultry to 1–2 servings per week to optimize metabolic health [61, 92].

### Food processing

Ultra-processed foods (UPFs), such as processed meats, refined grains and sugars, are convincingly linked to metabolic harms [61, 94]. However, most foods require some form of processing to be suitable for human consumption—e.g., chopping, cooking, smoking, freezing, or salting. The NOVA classification system provides a standardized approach to categorizing foods based on their processing level [95]. It divides foods into four main groups: unprocessed or minimally processed foods, processed culinary ingredients, processed foods, and UPFs. UPFs undergo extensive processing and typically contain multiple ingredients, including additives, preservatives, emulsifiers, dyes, color stabilizers, flavorings, and other synthetic substances. They are designed to be hyper-palatable, convenient, and have a long shelf life. UPFs are often ready-to-eat or ready-to-heat products and are characterized by high levels of refined carbohydrates, saturated fats, and salt, while being low in essential nutrients such as fiber [95].

A well-known crossover metabolic ward RCT by Hall et al. examined the effects of UPFs on energy intake and weight [96]. In this study, 20 adults consumed minimally processed and ultra-processed diets ad libitum over two 2-week periods. Meals were designed to be matched for calories, energy density, macronutrients, sugar, sodium,

and fiber. Participants consumed 508 kcal/day more on the UPF diet, resulting in a weight gain of 0.9 kg, whereas they lost 0.9 kg when switched to the minimally processed food (MPF) diet. A similar, smaller study from Japan found that overweight or obese individuals randomized to a UPF diet consumed 813 kcal/day more than those on a non-UPF diet, gaining 1.1 kg in just 1 week [97]. Interestingly, in both studies, the increased energy intake was due to greater consumption of carbohydrates and fats, but not protein. This finding supports the protein leverage hypothesis, which suggests that individuals consuming UPFs may overeat in an effort to meet protein requirements [98].

Most evidence linking UPF intake to obesity and CMD comes from observational studies. Multiple meta-analyses indicate that high UPF intake is associated with negative effects on weight management and CMH [99–101], a trend not observed with other NOVA food groups [50, 101]. While the mechanisms by which UPFs contribute to obesity are numerous, they remain inconclusive [101].

### Artificial sweeteners

Artificial sweeteners (AS) have been widely introduced into the food supply over the past few decades as a strategy to reduce sugar and calorie intake. A large meta-analysis found that substituting AS for sugary beverages was associated with small improvements in body weight and CMH [102]. AS are generally considered safe by regulatory agencies [103]; however, their long-term health effects remain unclear, and in 2022, the World Health Organization (WHO) issued guidelines advising against the use of AS [104, 105]. Recent studies have raised concerns about potential health risks associated with AS. One study found that plasma levels of erythritol, a widely used AS from the sugar alcohol family, were a strong predictor of major adverse cardiovascular events within 3 years [106]. Additionally, a large prospective observational study demonstrated a significant association between the consumption of several AS (including aspartame, acesulfame potassium, and sucralose) and an increased risk of cardiovascular events over a median follow-up period of 9 years [107]. Another study by the same group reported a positive association between AS intake and an elevated risk of T2DM [108].

In conclusion, recent evidence suggests that while replacing sugars with AS can lead to short-term reductions in body weight and may lower the risk of dental caries, their long-term use has been associated with an increased risk of T2DM, CVD, and mortality [105].

### Chocolate, coffee and tea

Dark chocolate and cocoa-based products may be beneficial for CMH due to their high flavonoid content, which can exert antioxidant, antihypertensive,

anti-inflammatory, and anti-atherogenic effects [109]. A recent meta-analysis showed that calorie-balanced increases in chocolate consumption were associated with lower overall, cardiovascular, and cancer mortality, with the primary benefit mediated by reduced blood pressure [110]. A Mendelian randomization study also found dark chocolate to be beneficial for hypertension and thromboembolism, though no association was observed with ten other CVDs [111]. Observational studies suggest that chocolate consumption may protect against insulin resistance [112] and abdominal obesity [113]. However, recent large meta-analyses, while generally highlighting the benefits of dark chocolate for CMH, note that the credibility of evidence is very low or low, emphasizing significant uncertainty regarding chocolate–disease associations [110, 114–117].

Coffee and tea are widely consumed beverages rich in caffeine and other bioactive compounds [118, 119]. The relationship between coffee consumption and the risk of CHD has been studied for over 60 years [120]. While early case–control studies suggested a positive association between coffee consumption and CHD risk, later prospective studies and meta-analyses have generally found no definitive association [121]. A 2013 cohort study reported that consuming four cups of coffee per day was linked to increased mortality [122]. However, a 2014 meta-analysis of prospective studies concluded that moderate coffee consumption was inversely associated with CVD risk, with the lowest risk observed at 3–5 cups per day [121]. These findings were corroborated by a recent prospective study involving over 170,000 individuals, which found that habitual caffeine intake, particularly at moderate levels, was associated with a lower risk of new-onset CMD [123]. Epidemiologic studies on caffeine intake are often confounded by factors such as smoking and other lifestyle behaviors. Early studies that did not adequately control for these biases led to misleading results, and residual confounding remains a concern even in more recent studies [119].

Given that caffeine is a purine derivative, its effects on serum uric acid levels, hyperuricemia, and gout are of interest. Several studies indicate that coffee consumption is associated with a lower risk of hyperuricemia [124]. For instance, a meta-analysis of observational studies found that higher coffee intake was linked to reduced serum uric acid levels and a lower risk of gout, particularly in men [125]. The effect appears to be dose-dependent, with greater benefits observed at higher levels of coffee consumption. Proposed mechanisms include coffee's ability to enhance uric acid excretion via the kidneys and the antioxidant effects of chlorogenic acid, a major polyphenol in coffee. Interestingly, studies suggest that these uric acid-lowering effects are likely attributable

to non-caffeine components, as similar benefits are observed with decaffeinated coffee [126].

A substantial body of evidence indicates that moderate caffeine intake is consistently associated with a reduced risk of chronic diseases and can be part of a healthy lifestyle.

### Alcohol

Alcohol induces acute anxiolytic effects in humans and has historically been used for this purpose [127]. While excessive alcohol-intake is a well-established risk factor for CMD, the association between mild-to-moderate alcohol consumption and CMH is complex.

Mild-to-moderate alcohol intake increases fatty acid oxidation and glucose uptake by muscle cells and may increase HDL-cholesterol, though the link to improved reverse cholesterol transport is controversial. Conversely, excessive alcohol consumption inhibits oxidation of fatty acids in the liver, leading to fatty acid accumulation, hypertriglyceridemia and eventually impairs glucose uptake increasing insulin resistance [128].

A majority of epidemiological studies suggest that mild-to-moderate alcohol consumption is associated with lower adverse cardiovascular events [127] and lower all-cause and cardiovascular mortality [129], but can increase the risk for cancer [127], atrial fibrillation, hemorrhagic stroke, adiposity and hypertension [53, 130]. Evidence supporting the protective effects of mild-to-moderate alcohol consumption is inconsistent and dietary guidelines discourage alcohol intake for CVD prevention [53, 55].

### Evidence regarding current popular diets

The Dietary Reference Intakes (DRI) include an Acceptable Macronutrient Distribution Range (AMDR) [52] recommendation that outlines a broad range of macronutrients for healthy nutritional intake: carbohydrates, 45–65%; fat, 20–35%; and protein, 10–35%. However, several popular dietary patterns fall outside these ranges, which may cause confusion. For example, very low-fat and ketogenic diets are lower in fat and carbohydrates, respectively, while Mediterranean diet can exceed the fat range, particularly due to its emphasis on extra-virgin olive oil. Compared to usual diet, popular diets generally can slightly improve cardiometabolic parameters at 6 month but differences largely disappear at 12 month, implying that people can choose the diet they prefer [131]. In the following, we aim to clarify the intended implementation of some of the most popular dietary patterns and summarize the evidence regarding their effects on CMH.



### Mediterranean

The Mediterranean diet is one of the most popular and is commonly ranked as one of the healthiest [132–134]. It has been shown to reduce the risk of heart disease, metabolic syndrome, and T2DM [135]. A landmark study followed 7,447 individuals at high cardiovascular risk over 4.8 years and showed a 30% lower incidence of major cardiovascular events among participants following the Mediterranean diet supplemented with extra-virgin olive oil or nuts, as compared to those assigned to a reduced-fat diet [132]. The group supplemented with extra-virgin olive oil aimed to consume  $\geq 50$  g/day of the polyphenol-rich olive oil, while those supplemented with nuts, were recommended to consume 30 g of nuts, composed of 15 g of walnuts, 7.5 g of almonds, and 7.5 g of hazelnuts. Recommendations for both Mediterranean diets included optional Wine with meals for habitual drinkers ( $\geq 7$  glasses/week).

Meta-analysis comparing different popular diets found Mediterranean diet as most effective dietary approach to improve glycemic control in patients with T2DM [136] and LDL cholesterol in general [131]. A systematic review ranked the Mediterranean diet as the most likely dietary model to provide protection against CHD [137]. The traditional Mediterranean diet is characterized by a high intake of olive oil, fruits, nuts, vegetables, and cereals; a moderate intake of fish and poultry; and a low intake of dairy products, red meat, processed meats, and sweets. It also can include wine in moderation, consumed with meals [132]. Guidance on sodium varies across different sources and includes both implicit and explicit recommendations (e.g., many Mediterranean patterns implicitly limit sodium by restricting the consumption of processed foods, which are a primary contributor of sodium). Recommendations for dairy foods vary across sources, with some advising limits and others advocating for the inclusion of yogurt and cheese, with little emphasis on differentiating between low-fat and whole-fat options. This dietary pattern is unique in its inclusion of moderate alcohol consumption [49].

The health effects of individual foods, together with the above results, provide strong evidence supporting a Mediterranean-type diet for CMH.

### DASH (dietary approaches to stop hypertension)

This dietary pattern is based on a large multicenter trial published in 1997, which examined the impact of dietary patterns on blood pressure in 459 adults. The study showed that a diet rich in fruits, vegetables, and low-fat dairy, with reduced saturated and total fats, can substantially lower blood pressure [138]. The sodium chloride content of each diet was similar—approximately 3 g per day. Relative to the control diet, it reduced systolic blood pressure by 5.5 mmHg and diastolic blood pressure by

3.0 mmHg. In 133 participants with hypertension, the diet produced a net reduction in systolic and diastolic blood pressure of 11.4 and 5.5 mmHg, respectively—a reduction similar in magnitude to that observed in trials of drug monotherapy for hypertension [138]. It was estimated that a population-wide reduction in blood pressure of this magnitude would reduce the incidence of coronary heart disease by  $\sim 15\%$  and stroke by  $\sim 27\%$  [138]. In a recent scientific statement from the American Heart Association (AHA) comparing popular diets, DASH-style patterns aligned best with AHA criteria, followed by the Mediterranean diet [49].

### Plant-based and portfolio diet

Vegetarian-style dietary patterns generally restrict animal products. There are several types of vegetarian diets, including Pescatarian (which excludes meat and poultry but includes fish, dairy, and eggs), Lacto-ovo-vegetarian (excludes meat, poultry, and fish), and vegan (excludes meat, poultry, fish, dairy, and eggs) [49].

A recent study that followed over 400,000 Americans for 20 years found that a diet with primarily fat from plant sources was associated with decreased mortality. Animal fat, on the other hand, was associated with an increased risk of death in this study [6]. However, distinguishing between animal and plant fats may be an oversimplification, as it is important to consider the composition. For example, fish fat, which provides important omega-3 fatty acids, is considered animal fat, while palm and coconut fats, although plant-based, contain unhealthy long-chain saturated fats.

Another large prospective cohort study, including over 70,000 Seventh-day Adventists between 2002 and 2007, found vegetarian diets to be associated with lower all-cause mortality compared to non-vegetarian diets [139]. It also found some associations with lower mortality for pescatarian, vegan, and lacto-ovo-vegetarian diets specifically, compared to non-vegetarian diets [139]. Vegetarian dietary patterns have also been associated with a lower risk of metabolic syndrome [140, 141] and a protective effect against T2DM, while pesco- and semi-vegetarian diets offered intermediate protection [141].

A specific form of plant-based diet is the Portfolio Diet, designed by David Jenkins to lower cholesterol and improve cardiovascular and metabolic health by combining known cholesterol-lowering foods. Initially tested on himself, it later showed in a small RCT of 46 healthy hyperlipidemic adults a maximal LDL-C lowering efficacy similar to that of 20 mg lovastatin ( $-28.6\%$  versus  $-30.9\%$ ) in a “head-to-head” comparison when all foods were provided under metabolically controlled conditions [29]. Key components include plant sterols (phytosterols, found in fortified foods), viscous fiber (from oats, barley, and legumes), soy protein (from tofu and soy

milk), and nuts. A subsequent longer-term multi-center RCT, including 351 participants with hyperlipidemia, showed smaller reductions of 10–15% under free-living conditions, with adherence only at 43% of the initial metabolic trial, as participants received only dietary advice [142]. In a systematic review and meta-analysis of seven trial comparisons, the Portfolio Diet significantly reduced LDL-C by ~17%, as well as apolipoprotein B, total cholesterol, triacylglycerols, blood pressure, and C-reactive protein. There was no effect on HDL-C or body weight [143].

It is essential to recognize that the quality of plant-based foods consumed plays a critical role in determining health outcomes [144]. One prospective investigation of a plant-based diet and the incidence of CVD found that healthier plant foods (i.e., whole grains, fruits, vegetables, nuts, legumes, oils, tea, and coffee) were associated with improved metabolic health, whereas less-healthy plant foods (i.e., fruit juices, sweetened beverages, refined grains, potatoes/fries, and sweets) were associated with an increased incidence of CVD [145].

In summary, a healthy plant-based diet emphasizes plant foods and minimizes animal products, offering numerous health benefits while promoting environmental sustainability.

#### Low-carbohydrate and ketogenic diets

Generally, low-carbohydrate (low-carb) diets produce similar or greater weight loss than low-fat diets, with corresponding improvements in blood pressure and lipid profiles [62]. A large 12-month weight loss study comparing healthy low-carb versus healthy low-fat diets showed no significant difference in weight loss. However, both groups experienced significant weight loss (–5.3 kg for the low-fat diet versus –6.0 kg for the low-carb diet) [68]. The focus of healthy low-carb diets is to reduce exposure to carbohydrates, especially ultra-processed foods rich in refined starches and sugars. This approach may explain why low-carb diets are the most effective for HbA1c reductions in a meta-analysis of dietary approaches [136]. Other meta-analyses further suggest that low-carb diets may be superior to low-fat diets for glycemic control in patients with T2DM [146, 147]. These diets emphasize vegetables, fruits, nuts and seeds, fish and seafood, and non-tropical oils, while limiting carbohydrate intake to 30–40% of daily calories. They focus on whole grains, legumes, and dairy, while minimizing foods rich in refined starches and sugars [49].

An extreme form of low-carb diet is the ketogenic diet, which consists of a high-fat component, very low carbohydrates, and adequate protein intake. Typically, energy intake from dietary carbohydrates is limited to less than 10% of daily intake [148, 149]. The ketogenic diet has been clinically used since the early 1920s to control

seizures in patients with epilepsy [150]. Recently, interest in the ketogenic diet has increased due to its beneficial effects in a number of diseases, including obesity [61, 151, 152], T2DM [151], high blood pressure [153], and cancer [149].

One study compared 262 diabetic patients undergoing a ketogenic diet to usual care over 1 year. The ketogenic diet led to a reduction in HbA1c from 7.6 to 6.3%, a 12% loss in body weight, and a significant reduction in medication use. These improvements occurred safely while dyslipidemia and markers of inflammation and liver function also improved [152]. However, a 2019 review of available data found that most improvements relative to a comparison diet were no longer significant after 12 months [154]. An elegant metabolic-ward study showed that participants on a cross-over ad libitum ketogenic animal-based diet consumed nearly 700 kcal more per day compared to a plant-based version, but there was no difference in weight gain [155]. Some challenges of the ketogenic diet include initial symptoms such as headache, fatigue, irritability, nausea, and constipation, which improve over time. However, the lack of benefits from fruits, vegetables, beans, legumes, and whole grains [49, 61] has led to official discouragement of the routine use of the ketogenic diet [54]. It may be most useful for initial weight loss (e.g., over 6–12 months), after which minimally processed, bioactive-rich foods can be gradually reintroduced. Potential long-term health effects require further investigation [61].

#### Paleo diet

The Paleo diet, or Paleolithic nutrition [156], is based on the idea that the typical food of late Paleolithic humans consisted of lean wild meats, fruits and non-starchy vegetables, which was very different from the modern diet that includes dairy, large portions of cereals, and highly processed foods [156]. The human diet evolved much more rapidly than our genetics, which developed before the advent of agriculture. Therefore, Paleolithic foods may be better suited to our pre-agricultural energy metabolism than the current modern diet [157]. A systematic review of four randomized controlled trials, involving 159 participants with one or more components of metabolic syndrome, found that Paleo diet resulted in greater short-term improvements in metabolic syndrome components compared to guideline-based control diets [158]. However, scientific evidence supporting the long-term health benefits of the Paleo diet is still lacking. A more recent systematic review and meta-analysis, which included 98 participants, found no evidence of greater health benefits from the Paleolithic diet compared to other healthy diets regarding glucose and insulin homeostasis in individuals with altered glucose metabolism [159].

## Emerging areas

### Intermittent fasting and time-restricted eating

Caloric restriction (CR) has been shown to extend lifespan in multiple species [160, 161] and has well-established benefits in CMH for humans, but many individuals find it difficult to sustain CR over the long-term. Intermittent fasting (IF), an alternative form of dietary restriction that may or may not include CR, can also improve CMH and is potentially more sustainable in humans. Interest in IF has been growing, with both animal and human studies exploring its effects. There are different forms of IF, ranging from time-restricted eating (TRE) with a limited number of hours, to alternate-day fasting, or fasting for 2 days per week. The most common form of IF typically involves 12–23 h of fasting per day [51, 88].

The reported beneficial effects of IF, particularly through a pattern of TRE, are based on improvements in metabolic balance by stabilizing circadian rhythms and initiating a process called metabolic switching [162]. A metabolic switch occurs when a negative energy balance is reached, usually at least 12 h after stopping food intake. At this point, hepatic glycogen stores are depleted, and fatty acids are released from adipose tissue through lipolysis. The metabolic shift from glucose metabolism to the use of fatty acids and ketones represents an evolutionarily conserved mechanism. This shift redirects metabolism from lipid and cholesterol synthesis and storage to the mobilization of fat through fatty acid oxidation and ketone production, helping preserve muscle mass and function [162, 163].

At the cellular level, the delayed aging phenotype associated with IF is linked to increased metabolite recycling, autophagy, and enhanced maintenance and repair mechanisms tied to stress response pathways. The overall result is a reprogrammed metabolism with improved repair and recycling processes, with improved inflammation and oxidative stress [164, 165] as well as reduced growth and macromolecular synthesis [87, 88, 162].

Nonetheless, the extent to which these mechanistic pathways confer clinical advantages independent of weight loss remains uncertain.

Most human clinical trials on IF have focused on weight loss or improvements in cardiometabolic biomarkers, typically involving subjects with CMD and using an 6–12 h daily eating window [166–172].

A landmark 12-month human RCT involving 139 participants with obesity compared TRE with CR or daily CR alone. It found similar improvements in weight loss (–8.0 kg for the TRE group vs –6.3 kg for the CR group) and metabolic parameters, suggesting that CR accounted for most of the improvements seen with TRE [173]. Similarly, another major 12-week human trial with 116 adults (BMI > 25) found that TRE, in the absence of other interventions, was not more effective for weight loss than

eating throughout the day [174]. A more recent large RCT over 12 weeks including 197 adults with overweight or obesity compared early-, late- and self-selected 8 h TRE to usual care (education about the Mediterranean diet). Visceral adiposity measured by magnetic resonance imaging (primary outcome) was similar in all four groups. However, all TRE groups decreased the energy intake by 300–500 kcal daily, which led to an average weight loss of approximately 3 kg compared with the usual care group. Furthermore, they observed a significant decrease in fasting glucose levels in the early TRE group compared with the other three groups [175].

Other smaller studies found that IF can lead to modest weight loss without significant CR [176–178]. One small study even reported a reduction in caloric intake by 550 kcal/day without calorie counting [179].

A meta-analysis of 13 randomized controlled/comparison trials with matched energy intakes (isocaloric) between IF and CR found similar benefit in CMH compared with CR, with very limited evidence suggesting that IF may be more effective versus CR for fat loss and insulin sensitivity [167]. Another meta-analysis of 7 studies found that addition of TRE to CR produced greater weight loss and improvements in CMH in 3 of the 7 studies [166]. When no CR is intended however, TRE appeared to be more effective for weight loss and improved CMH compared to other diet interventions in a meta-analysis of 12 studies; moreover early TRE was more beneficial for weight loss and CMH than delayed TRE [171].

Another recent meta-analysis found that TRE significantly improved CMH parameters, identifying an optimal feeding window of 6–12 h, differentiated for specific parameters, with the last eating time point at 6–8 PM [172]. Another group confirmed these findings in their meta-analysis, reporting that a TRE regimen of 6–10 h over 5–14 weeks improved glycemic parameters in individuals with overweight, obesity, or T2DM. Eating early in the day provided greater benefits for some glycemic parameters [170].

In conclusion, TRE appears to be a safe and effective dietary approach to improve CMH and weight reduction in adults with CMD compared with ad libitum eating. Early TRE may be more beneficial for glucose homeostasis than delayed TRE. When directly compared with CR the results are less clear, yet the addition of TRE to CR interventions can produce greater weight loss and improvements in CMH in some circumstances. Additional research is needed to further clarify the specific circumstances in which the addition of TRE does or does not provide benefits to CR interventions.

### Gut microbiome

Traditionally, “germs” have been associated with infection and disease, but in the past decade, there has been an explosion of interest and research on the microbiota and its important role in protecting against pathogens through the “education” of the immune system [180], as well as its involvement in multiple processes related to cardiometabolic and neurological health [180].

Fecal transplantation from obese female twins into germ-free mice led to increased total body and fat mass, as well as obesity-associated metabolic phenotypes. In contrast, mice receiving microbiota from the lean co-twin prevented the development of these changes [181]. Another experiment found that infusion of gut microbiota from lean donors improved insulin resistance in patients with metabolic syndrome [182]. These early experiments highlighting the importance of gut microbiome have recently been translated into human, double-blind RCTs. Recently, microbiota-directed food interventions have been found to be an effective dietary supplementation strategy for undernourished children [183–185]. Two RCTs showed significant improvements in glucose metabolism in adults [186, 187].

### Practical recommendations for cardiometabolic health

Despite the often striking differences in recommendations across dietary patterns, high-quality diets from all approaches tend to converge on similar principles. There is near-universal agreement to prioritize vegetables and whole foods, while reducing or avoiding sugar and refined grains. There is also widespread consensus that fruits, nuts, seeds, fish, and healthy vegetable oils can be integral components of a healthy diet and are consistent with current nutrition guidelines [53].

Focusing on improving adherence to these shared recommendations would be a significant step forward in reducing the prevalence of CMD.

### Abbreviations

AHA	American Heart Association
AMDR	Acceptable macronutrient distribution range
AS	Artificial sweeteners
CETP	Cholesteryl ester transfer protein
CHD	Coronary heart disease
CMD	Cardiometabolic disease
CMH	Cardiometabolic health
CVD	Cardiovascular diseases
DASH	Dietary approaches to stop hypertension
DRI	Dietary reference intakes
GH	Growth hormone
GLP-1	Glucagon-like peptide 1
HCAR	Hydroxycarboxylic acid receptors
HDL	High-density lipoprotein
IF	Intermittent fasting
IGF-1	Insulin-like growth factor 1
LDL	Low-density lipoprotein
MPF	Minimally processed food
MUFA	Monounsaturated fatty acid
PUFA	Polyunsaturated fatty acid

PYY	Peptide YY
RCT	Randomized controlled trial
RDA	Recommended dietary allowance
SFA	Saturated fatty acids
T2DM	Type 2 diabetes mellitus
TRE	Time-restricted eating
UPF	Ultra-processed food
WHO	World Health Organization

### Author contributions

E.G., D.L.D. and M.B. contributed to the conception or design of the main manuscript. E.G., T.S. and A.G. drafted the manuscript. All authors revised the manuscript. All gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy.

### Funding

Open Access funding enabled and organized by Projekt DEAL. This work was supported by the German Research Foundation (DFG), Collaborative Research Centre (CRC) 1052—“Obesity Mechanisms,” awarded to D.L.D., T.S., M.G., and A.G.

### Data availability

No datasets were generated or analysed during the current study.

### Declarations

#### Competing interests

The authors declare no competing interests.

Received: 13 March 2025 / Accepted: 29 April 2025

Published online: 31 May 2025

### References

1. Tahir UA, Gerszten RE. Molecular biomarkers for cardiometabolic disease: risk assessment in young individuals. *Circ Res*. 2023;132(12):1663–73. <https://doi.org/10.1161/CIRCRESAHA.123.322000>.
2. Koskinas KC, Van Craenenbroeck EM, Antoniadou C, et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. *Eur Heart J*. 2024;00:1–36. <https://doi.org/10.1093/eurheartj/ehae508>.
3. Gjermani E, Kirstein AS, Kolbig F, et al. Obesity—an update on the basic pathophysiology and review of recent therapeutic advances. *Biomolecules*. 2021. <https://doi.org/10.3390/biom11101426>.
4. The top 10 causes of death. <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>. Accessed 22 Sep 2024.
5. Micha R, Peñalvo JL, Cudhea F, Imamura F, Rehm CD, Mozaffarian D. Association between dietary factors and mortality from heart disease, stroke, and type 2 diabetes in the United States. *JAMA*. 2017;317(9):912. <https://doi.org/10.1001/JAMA.2017.0947>.
6. Zhao B, Gan L, Graubard BI, et al. Plant and animal fat intake and overall and cardiovascular disease mortality. *JAMA Intern Med*. 2024. <https://doi.org/10.1001/JAMAINTERNMED.2024.3799>.
7. Tran KB, Lang JJ, Compton K, et al. The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the global burden of disease study 2019. *Lancet*. 2022;400(10352):563–91. [https://doi.org/10.1016/S0140-6736\(22\)01438-6](https://doi.org/10.1016/S0140-6736(22)01438-6).
8. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the lancet standing commission. *Lancet*. 2024;404(10452):572–628. [https://doi.org/10.1016/S0140-6736\(24\)01296-0](https://doi.org/10.1016/S0140-6736(24)01296-0).
9. Lean ME, Leslie WS, Barnes AC, et al. 5-year follow-up of the randomised diabetes remission clinical trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. *Lancet Diabetes Endocrinol*. 2024;12(4):233–46. [https://doi.org/10.1016/S2213-8587\(23\)00385-6](https://doi.org/10.1016/S2213-8587(23)00385-6).
10. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the american heart association. *Circulation*. 2023;148(20):1606–35.
11. San-Millán I. Assessing metabolic flexibility and mitochondrial bioenergetics. In: *Clinical Bioenergetics*. Elsevier; 2021:245–268. <https://doi.org/10.1016/B978-0-12-819621-2.00010-3>



12. The Lancet Diabetes & Endocrinology. Metabolic health: a priority for the post-pandemic era. *Lancet Diabetes Endocrinol.* 2021;9(4):189. [https://doi.org/10.1016/S2213-8587\(21\)00058-9](https://doi.org/10.1016/S2213-8587(21)00058-9).
13. Osaka N, Sasaki AT. Beyond Warburg: LDHA activates RAC for tumour growth. *Nat Metab.* 2022;4(12):1623–5. <https://doi.org/10.1038/s42255-022-00709-3>.
14. Otvos JD, Shalaurou I, May HT, et al. Multimarkers of metabolic malnutrition and inflammation and their association with mortality risk in cardiac catheterisation patients: a prospective, longitudinal, observational, cohort study. *Lancet Heal Longev.* 2023;4(2):e72–82. [https://doi.org/10.1016/S2666-7568\(23\)00001-6](https://doi.org/10.1016/S2666-7568(23)00001-6).
15. Kumar S, Connors KM, Shearer JJ, et al. Frailty and metabolic vulnerability in heart failure: a community cohort study. *J Am Heart Assoc.* 2024. <https://doi.org/10.1161/JAHA.123.031616>.
16. Connors KM, Shearer JJ, Joo J, et al. The metabolic vulnerability index: a novel marker for mortality prediction in heart failure. *JACC Hear Fail.* 2024;12(2):290–300. <https://doi.org/10.1016/J.JCHF.2023.06.013>.
17. Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. *Lancet Diabetes Endocrinol.* 2019;7(9):715–25. [https://doi.org/10.1016/S2213-8587\(19\)30084-1](https://doi.org/10.1016/S2213-8587(19)30084-1).
18. O'Hearn M, Lauren BN, Wong JB, Kim DD, Mozaffarian D. Trends and disparities in cardiometabolic health among US adults, 1999–2018. *J Am Coll Cardiol.* 2022;80(2):138–51. <https://doi.org/10.1016/J.JACC.2022.04.046>.
19. Morze J, Danielewicz A, Hoffmann G, Schwingshackl L. Diet quality as assessed by the healthy eating index, alternate healthy eating index, dietary approaches to stop hypertension score, and health outcomes: a second update of a systematic review and meta-analysis of cohort studies. *J Acad Nutr Diet.* 2020;120(12):1998–2031.e15. <https://doi.org/10.1016/J.JAND.2020.08.076>.
20. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. *Diabetes Care.* 2009. <https://doi.org/10.2337/DC09-5302>.
21. Taylor R, Al-Mrabeh A, Sattar N. Understanding the mechanisms of reversal of type 2 diabetes. *Lancet Diabetes Endocrinol.* 2019;7(9):726–36. [https://doi.org/10.1016/S2213-8587\(19\)30076-2](https://doi.org/10.1016/S2213-8587(19)30076-2).
22. Merz KE, Thurmond DC. Role of skeletal muscle in insulin resistance and glucose uptake. *Compr Physiol.* 2020;10(3):785. <https://doi.org/10.1002/CPHY.C190029>.
23. Farbstein D, Levy AP. HDL dysfunction in diabetes: causes and possible treatments. *Expert Rev Cardiovasc Ther.* 2012;10(3):353. <https://doi.org/10.1586/ER.C.11.182>.
24. Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. *Cardiovasc Diabetol.* 2018. <https://doi.org/10.1186/S12933-018-0762-4>.
25. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL—guardian angel of the arterial wall? *Nat Clin Pract Cardiovasc Med.* 2006;3(3):144–53. <https://doi.org/10.1038/NPCARDIO0500>.
26. Van Deursen D, Jansen H, Verhoeven AJM. Glucose increases hepatic lipase expression in HepG2 liver cells through upregulation of upstream stimulatory factors 1 and 2. *Diabetologia.* 2008;51(11):2078–87. <https://doi.org/10.1007/S00125-008-1125-6>.
27. Lewis GF, Murdoch S, Uffelman K, et al. Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone. *Diabetes.* 2004;53(11):2893–900. <https://doi.org/10.2337/DIABES.53.11.2893>.
28. Vartiainen E, Laatikainen T, Peltonen M, et al. Thirty-five-year trends in cardiovascular risk factors in Finland. *Int J Epidemiol.* 2010;39(2):504–18. <https://doi.org/10.1093/IJE/DYP330>.
29. Jenkins DJA, Kendall CWC, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. *JAMA.* 2003;290(4):502–10. <https://doi.org/10.1001/jama.290.4.502>.
30. Wadhera RK, Steen DL, Khan I, Giugliano RP, Foody JM. A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. *J Clin Lipidol.* 2016;10(3):472–89. <https://doi.org/10.1016/j.jacl.2015.11.010>.
31. Stearns SC. Evolutionary medicine: its scope, interest and potential. *Proc R Soc B Biol Sci.* 2012;279(1746):4305. <https://doi.org/10.1098/RSPB.2012.1326>.
32. Rubio-Ruiz ME, Peredo-Escárrega AE, Cano-Martínez A, Guarnier-Lans V. An evolutionary perspective of nutrition and inflammation as mechanisms of cardiovascular disease. *Int J Evol Biol.* 2015;2015:1–10. <https://doi.org/10.1155/2015/179791>.
33. Lüdecke T, Leichliter JN, Stratford D, et al. *Australopithecus* at Sterkfontein did not consume substantial mammalian meat. *Science.* 2025;387(6731):309–14. <https://doi.org/10.1126/SCIENCE.ADQ7315>.
34. Warinner C, Hendy J, Speller C, et al. Direct evidence of milk consumption from ancient human dental calculus. *Sci Rep.* 2014;4(1):1–6. <https://doi.org/10.1038/srep07104>.
35. Weyrich LS, Duchene S, Soubrier J, et al. Neanderthal behaviour, diet, and disease inferred from ancient DNA in dental calculus. *Nat.* 2017;544(7650):357–61. <https://doi.org/10.1038/nature21674>.
36. Shipley GP, Kindscher K. Evidence for the paleoethnobotany of the neanderthal: a review of the literature. *Scientifica.* 2016. <https://doi.org/10.1155/2016/8927654>.
37. Power RC, Salazar-García DC, Rubini M, et al. Dental calculus indicates widespread plant use within the stable Neanderthal dietary niche. *J Hum Evol.* 2018;119:27–41. <https://doi.org/10.1016/J.JHEVOL.2018.02.009>.
38. Jaouen K, Richards MP, Le CA, et al. Exceptionally high  $\delta^{15}\text{N}$  values in collagen single amino acids confirm Neandertals as high-trophic level carnivores. *Proc Natl Acad Sci USA.* 2019;116(11):4928–33. <https://doi.org/10.1073/PNAS.1814087116>.
39. Peters A, Krumbholz P, Jäger E, et al. Metabolites of lactic acid bacteria present in fermented foods are highly potent agonists of human hydroxycarboxylic acid receptor 3. *PLoS Genet.* 2019. <https://doi.org/10.1371/JOURNAL.PGE1008145>.
40. Wu Y, Tao D, Wu X, Liu W, Cai Y. Diet of the earliest modern humans in East Asia. *Front Plant Sci.* 2022;13: 989308. <https://doi.org/10.3389/FPLS.2022.989308/FULL>.
41. Hendy J, Warinner C, Bouwman A, et al. Proteomic evidence of dietary sources in ancient dental calculus. *Proc Biol Sci.* 2018. <https://doi.org/10.1098/RSPB.2018.0977>.
42. Velsko IM, Fellows Yates JA, Aron F, et al. Microbial differences between dental plaque and historic dental calculus are related to oral biofilm maturation stage. *Microbiome.* 2019. <https://doi.org/10.1186/S40168-019-0717-3>.
43. Kazarina A, Petersone-gordina E, Kimsis J, et al. The postmedieval latvian oral microbiome in the context of modern dental calculus and modern dental plaque microbial profiles. *Genes.* 2021;12(2):1–16. <https://doi.org/10.3390/GENES12020309>.
44. Raichlen DA, Pontzer H, Harris JA, et al. Physical activity patterns and biomarkers of cardiovascular disease risk in hunter-gatherers. *Am J Hum Biol.* 2017. <https://doi.org/10.1002/AJHB.22919>.
45. Sayre MK, Anyawire M, Paolo B, et al. Lifestyle and patterns of physical activity in Hadza foragers. *Am J Biol Anthropol.* 2023;182(3):340–56. <https://doi.org/10.1002/AJPA.24846>.
46. Yokose C, McCormick N, Rai SK, et al. Effects of low-fat, mediterranean, or low-carbohydrate weight loss diets on serum urate and cardiometabolic risk factors: a secondary analysis of the dietary intervention randomized controlled trial (DIRECT). *Diabetes Care.* 2020;43(11):2812. <https://doi.org/10.2337/DC20-1002>.
47. Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. *N Engl J Med.* 2008;359(3):229–41. <https://doi.org/10.1056/NEJMOA0708681>.
48. Estruch R, Martínez-González MA, Corella D, et al. Effect of a high-fat Mediterranean diet on bodyweight and waist circumference: a prespecified secondary outcomes analysis of the PREDIMED randomised controlled trial. *Lancet Diabetes Endocrinol.* 2019;7(5):e6–17. [https://doi.org/10.1016/S2213-8587\(19\)30074-9](https://doi.org/10.1016/S2213-8587(19)30074-9).
49. Gardner CD, Vadeveloo MK, Petersen KS, et al. Popular dietary patterns: alignment with american heart association 2021 dietary guidance: a scientific statement from the American heart association. *Circulation.* 2023;147(22):1715–30. <https://doi.org/10.1161/CIR.0000000000001146>.
50. Pagidipati NJ, Taub PR, Ostfeld RJ, Kirkpatrick CF. Dietary patterns to promote cardiometabolic health. *Nat Rev Cardiol.* 2024;2024:1–9. <https://doi.org/10.1038/S41569-024-01061-7>.
51. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. *N Engl J Med.* 2017;376(3):254–66. <https://doi.org/10.1056/NEJMra1514009>.
52. Trumbo P, Schlicker S, Yates AA, Poos M. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. *J Am Diet Assoc.* 2002;102(11):1621–30. [https://doi.org/10.1016/S0002-8223\(02\)90346-9](https://doi.org/10.1016/S0002-8223(02)90346-9).
53. Visseren F, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of

- the European society of cardiology and 12 medical societies With. *Eur Heart J*. 2021;42(34):3227–337. <https://doi.org/10.1093/EURHEARTJ/EHAB484>.
54. Aas AM, Axelsen M, Churuangsk C, et al. Evidence-based European recommendations for the dietary management of diabetes. *Diabetol*. 2023;66(6):965–85. <https://doi.org/10.1007/S00125-023-05894-8>.
55. Lichtenstein AH, Appel LJ, Vadiveloo M, et al. 2021 dietary guidance to improve cardiovascular health: a scientific statement from the American heart association. *Circulation*. 2021;144(23):E472–87. <https://doi.org/10.1161/CIR.0000000000001031>.
56. SECTION 1 Foundation for healthy eating—Canada's Food Guide. <https://food-guide.canada.ca/en/guidelines/section-1-foundation-healthy-eating/>. Accessed 27 Sep 2024.
57. Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term weight gain in women and men A B S T R A C T. *N Engl J Med*. 2011;364:2392–404.
58. Lara-Castor L, Michá R, Cudhea F, et al. Intake of sugar sweetened beverages among children and adolescents in 185 countries between 1990 and 2018: population based study. *BMJ*. 2024;386(August):e079234. <https://doi.org/10.1136/bmj-2024-079234>.
59. Lee JJ, Khan TA, McGlynn N, et al. Relation of change or substitution of low- and no-calorie sweetened beverages with cardiometabolic outcomes: a systematic review and meta-analysis of prospective cohort studies. *Diabetes Care*. 2022;45(8):1917–30. <https://doi.org/10.2337/DC21-2130>.
60. Malik VS, Hu FB. The role of sugar-sweetened beverages in the global epidemics of obesity and chronic diseases. *Nat Rev Endocrinol*. 2022;18(4):205–18. <https://doi.org/10.1038/S41574-021-00627-6>.
61. Mozaffarian D. Dietary and policy priorities to reduce the global crises of obesity and diabetes. *Nat Food*. 2020;1(1):38–50. <https://doi.org/10.1038/s43016-019-0013-1>.
62. Tobias DK, Chen M, Manson JAE, Ludwig DS, Willett W, Hu FB. Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol*. 2015;3(12):968–79. [https://doi.org/10.1016/S2213-8587\(15\)00367-8](https://doi.org/10.1016/S2213-8587(15)00367-8).
63. Huntriss R, Campbell M, Bedwell C. The interpretation and effect of a low-carbohydrate diet in the management of type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials. *Eur J Clin Nutr*. 2018;72(3):311–25. <https://doi.org/10.1038/s41430-017-0019-4>.
64. Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. *Lancet*. 2019;393(10170):434–45. [https://doi.org/10.1016/S0140-6736\(18\)31809-9](https://doi.org/10.1016/S0140-6736(18)31809-9).
65. Cummings JH, Engineer A. Denis Burkitt and the origins of the dietary fibre hypothesis. *Nutr Res Rev*. 2018;31(1):1–15. <https://doi.org/10.1017/S0954422417000117>.
66. Wu JHY, Michá R, Mozaffarian D. Dietary fats and cardiometabolic disease: mechanisms and effects on risk factors and outcomes. *Nat Rev Cardiol*. 2019;16(10):581–601. <https://doi.org/10.1038/S41569-019-0206-1>.
67. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. *N Engl J Med*. 2009;360(9):859–73. <https://doi.org/10.1056/NEJMOA0804748>.
68. Gardner CD, Trepanowski JF, Gobbo LCD, et al. Effect of low-fat vs low-carbohydrate diet on 12-month weight loss in overweight adults and the association with genotype pattern or insulin secretion: the DIETFITS randomized clinical trial. *JAMA*. 2018;319(7):667–79. <https://doi.org/10.1001/JAMA.2018.0245>.
69. Ross R, Blair SN, Arena R, Church TS, Després JP, Franklin BA, Haskell WL, Kaminsky LA, Levine BD, Lavie CJ, Myers J. Importance of assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign: a scientific statement from the American heart association. *Circulation*. 2016;134(24):e653–99. <https://doi.org/10.1161/CIR.0000000000000461>.
70. McGuire S. Scientific Report of the 2015 Dietary Guidelines Advisory Committee. Washington, DC: US Departments of Agriculture and Health and Human Services, 2015. *Adv Nutr*. 2016;7(1):202–204. <https://doi.org/10.3945/AN.115.011684>.
71. Total fat intake for the prevention of unhealthy weight gain in adults and children: WHO guideline summary. <https://iris.who.int/handle/10665/375574>. Accessed 27 Sept, 2024.
72. Hooper L, Martin N, Jimoh OF, Kirk C, Foster E, Abdelhamid AS. Reduction in saturated fat intake for cardiovascular disease. *Cochrane Database Syst Rev*. 2020;2020(8).
73. Arnesen EK, Laake I, Veierød MB, Retterstøl K. Saturated fatty acids and total and CVD mortality in Norway: a prospective cohort study with up to 45 years of follow-up. *Br J Nutr*. 2024. <https://doi.org/10.1017/S0007114524001351>.
74. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J*. 2020;41(2):255–323. <https://doi.org/10.1093/eurheartj/ehz486>.
75. Simopoulos AP, DiNicolantonio JJ. The importance of a balanced  $\omega$ -6 to  $\omega$ -3 ratio in the prevention and management of obesity. *Open Hear*. 2016. <https://doi.org/10.1136/OPENHRT-2015-000385>.
76. Wu JHY, Marklund M, Imamura F, et al. Omega-6 fatty acid biomarkers and incident type 2 diabetes: pooled analysis of individual-level data for 39 740 adults from 20 prospective cohort studies. *Lancet Diabetes Endocrinol*. 2017;5(12):965. [https://doi.org/10.1016/S2213-8587\(17\)30307-8](https://doi.org/10.1016/S2213-8587(17)30307-8).
77. Huth PJ, Park KM. Influence of dairy product and milk fat consumption on cardiovascular disease risk: a review of the evidence. *Adv Nutr*. 2012;3(3):266–85. <https://doi.org/10.3945/AN.112.002030>.
78. Dukuzimana J, Janzi S, Habberstad C, Zhang S, Borné Y, Sonestedt E. High consumption of dairy products and risk of major adverse coronary events and stroke in a Swedish population. *Br J Nutr*. 2023;131(3):500. <https://doi.org/10.1017/S0007114523001939>.
79. Wastyk HC, Fragiadakis GK, Perelman D, et al. Gut-microbiota-targeted diets modulate human immune status. *Cell*. 2021;184(16):4137–4153.e14. <https://doi.org/10.1016/J.CELL.2021.06.019/ATTACHMENT/C644DBC5-0C28-4053-AE66-7C364E277F5E/MMC2.XLSX>.
80. Dehghan M, Mente A, Rangarajan S, et al. Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries. *Am J Clin Nutr*. 2020;111(4):795–803. <https://doi.org/10.1093/AJCN/NQZ348>.
81. Galvis Y, Pineda K, Zapata J, Aristizabal J, Estrada A, Fernandez ML, Barona-Acevedo J. Consumption of eggs alone or enriched with annatto (*Bixa orellana* L.) does not increase cardiovascular risk in healthy adults—a randomized clinical trial, the Eggant study. *Nutrients*. 2023;15(2):369.
82. Layman DK, Anthony TG, Rasmussen BB, et al. Defining meal requirements for protein to optimize metabolic roles of amino acids. *Am J Clin Nutr*. 2015;101(6):1330S–1338S. <https://doi.org/10.3945/AJCN.114.084053>.
83. Morton RW, Murphy KT, McKellar SR, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. *Br J Sports Med*. 2017;52(6):376. <https://doi.org/10.1136/BJSPORTS-2017-097608>.
84. De LC, Tsauo JY, Wu YT, et al. Effects of protein supplementation combined with resistance exercise on body composition and physical function in older adults: a systematic review and meta-analysis. *Am J Clin Nutr*. 2017;106(4):1078–91. <https://doi.org/10.3945/AJCN.116.143594>.
85. Van Nielen M, Feskens EJM, Mensink M, et al. Dietary protein intake and incidence of type 2 diabetes in Europe: the EPIC-InterAct case-cohort study. *Diabetes Care*. 2014;37(7):1854–62. <https://doi.org/10.2337/DC13-2627/-/DC1>.
86. Sluijs I, Beulens JWW, Van Der ADL, Spijkerman AMW, Grobbee DE, Van Der Schouw YT. Dietary intake of total, animal, and vegetable protein and risk of type 2 diabetes in the European prospective investigation into cancer and nutrition (EPIC)-NL study. *Diabetes Care*. 2010;33(1):43–8. <https://doi.org/10.2337/DC09-1321>.
87. Longo VD, Di Tano M, Mattson MP, Guidi N. Intermittent and periodic fasting, longevity and disease. *Nat aging*. 2021;1(1):47–59. <https://doi.org/10.1038/S43587-020-00013-3>.
88. Longo VD, Anderson RM. Nutrition, longevity and disease: from molecular mechanisms to interventions. *Cell*. 2022;185(9):1455–70. <https://doi.org/10.1016/J.CELL.2022.04.002>.
89. Levine ME, Suarez JA, Brandhorst S, et al. Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. *Cell Metab*. 2014;19(3):407–17. <https://doi.org/10.1016/J.CMET.2014.02.006>.
90. Gardner CD, Hartle JC, Garrett RD, Offringa LC, Wasserman AS. Maximizing the intersection of human health and the health of the environment with regard to the amount and type of protein produced and consumed in the United States. *Nutr Rev*. 2019;77(4):197. <https://doi.org/10.1093/NUTRIT/NUY073>.
91. Rand WM, Pellett PL, Young VR. Meta-analysis of nitrogen balance studies for estimating protein requirements in healthy adults. *Am J Clin Nutr*. 2003;77(1):109–27. <https://doi.org/10.1093/AJCN/77.1.109>.
92. Li C, Bishop TRP, Imamura F, et al. Meat consumption and incident type 2 diabetes: an individual-participant federated meta-analysis of 1.97 million adults

- with 100 000 incident cases from 31 cohorts in 20 countries. *Lancet Diabetes Endocrinol.* 2024;12(9):619–30. [https://doi.org/10.1016/S2213-8587\(24\)00179-7/ATTACHMENT/552FF16E-13EA-4EDA-BEE5-4F64078B967C/MMC1.PDF](https://doi.org/10.1016/S2213-8587(24)00179-7/ATTACHMENT/552FF16E-13EA-4EDA-BEE5-4F64078B967C/MMC1.PDF).
93. Ye J, Yu Q, Mai W, Liang P, Liu X, Wang Y. Dietary protein intake and subsequent risk of type 2 diabetes: a dose–response meta-analysis of prospective cohort studies. *Acta Diabetol.* 2019;56(8):851–70. <https://doi.org/10.1007/S00592-019-01320-X/METRICS>.
94. Monteiro CA, Moubarac JC, Levy RB, Canella DS, Da Costa Louzada ML, Cannon G. Household availability of ultra-processed foods and obesity in nineteen European countries. *Public Health Nutr.* 2018;21(1):18–26. <https://doi.org/10.1017/S1368980017001379>.
95. Monteiro CA, Cannon G, Moubarac JC, Levy RB, Louzada MLC, Jaime PC. The UN decade of nutrition, the NOVA food classification and the trouble with ultra-processing. *Public Health Nutr.* 2018;21(1):5–17. <https://doi.org/10.1017/S1368980017000234>.
96. Hall KD, Ayuketah A, Brychta R, et al. Ultra-processed diets cause excess calorie intake and weight gain: an inpatient randomized controlled trial of ad libitum food intake. *Cell Metab.* 2019;30(1):67. <https://doi.org/10.1016/J.CMET.2019.05.008>.
97. Hamano S, Sawada M, Aihara M, et al. Ultra-processed foods cause weight gain and increased energy intake associated with reduced chewing frequency: a randomized, open-label, crossover study. *Diabetes Obes Metab.* 2024;26(11):5431–43. <https://doi.org/10.1111/DOM.15922>.
98. Martínez Steele E, Raubenheimer D, Simpson SJ, Baraldi LG, Monteiro CA. Ultra-processed foods, protein leverage and energy intake in the USA. *Public Health Nutr.* 2018;21(1):114–24. <https://doi.org/10.1017/S1368980017001574>.
99. Askari M, Heshmati J, Shahinfar H, Tripathi N, Daneshzad E. Ultra-processed food and the risk of overweight and obesity: a systematic review and meta-analysis of observational studies. *Int J Obes.* 2020;44(10):2080–91. <https://doi.org/10.1038/S41366-020-00650-Z>.
100. Pagliai G, Dinu M, Madarena MP, Bonaccio M, Iacoviello L, Sofi F. Consumption of ultra-processed foods and health status: a systematic review and meta-analysis. *Br J Nutr.* 2021;125(3):308–18. <https://doi.org/10.1017/S0007114520002688>.
101. Dicken SJ, Batterham RL. Ultra-processed food and obesity: what is the evidence? *Curr Nutr Rep.* 2024;13(1):23–38. <https://doi.org/10.1007/S13668-024-00517-Z/TABLES/2>.
102. McGlynn ND, Khan TA, Wang L, Zhang R, Chiavaroli L, Au-Yeung F, Lee JJ, Noronha JC, Comelli EM, Mejia SB, Ahmed A. Association of low- and no-calorie sweetened beverages as a replacement for sugar-sweetened beverages with body weight and cardiometabolic risk: a systematic review and meta-analysis. *JAMA Network Open.* 2022;5(3):e222092. <https://doi.org/10.1001/jamanetworkopen.2022.2092>.
103. Rizas KD, Sams LE, Massberg S. Non-nutritional sweeteners and cardiovascular risk. *Nat Med.* 2023;29(3):539–40. <https://doi.org/10.1038/s41591-023-02245-3>.
104. WHO. WHO Advises Not to Use Non-sugar Sweeteners for Weight Control in Newly Released Guideline. [https://www.who.int/news/item/15-05-2023-who-advises-not-to-use-non-sugar-sweeteners-for-weight-control-in-newly-released-guideline?utm\\_source=chatgpt.com](https://www.who.int/news/item/15-05-2023-who-advises-not-to-use-non-sugar-sweeteners-for-weight-control-in-newly-released-guideline?utm_source=chatgpt.com). Accessed 14 Jan 2025.
105. WHO. *Health Effects of the Use of Non-Sugar Sweeteners: A Systematic Review and Meta-Analysis*; 2022. <https://www.who.int/publications/i/item/9789240046429>.
106. Witkowski M, Nemet I, Alamri H, et al. The artificial sweetener erythritol and cardiovascular event risk. *Nat Med.* 2023;29(3):710–8. <https://doi.org/10.1038/s41591-023-02223-9>.
107. Debras C, Chazelas E, Sellem L, et al. Artificial sweeteners and risk of cardiovascular diseases: results from the prospective NutriNet-Santé cohort. *BMJ.* 2022. <https://doi.org/10.1136/BMJ-2022-071204>.
108. Debras C, Deschasaux-Tanguy M, Chazelas E, et al. Artificial sweeteners and risk of type 2 diabetes in the prospective NutriNet-Santé cohort. *Diabetes Care.* 2023;46(9):1681–90. <https://doi.org/10.2337/dc23-0206>.
109. Berends LM, Van Der Velpen V, Cassidy A. Flavan-3-ols, theobromine, and the effects of cocoa and chocolate on cardiometabolic risk factors. *Curr Opin Lipidol.* 2015;26(1):10–9. <https://doi.org/10.1097/MOL.0000000000000144>.
110. Zhao B, Gan L, Yu K, Männistö S, Huang J, Albanes D. Relationship between chocolate consumption and overall and cause-specific mortality, systematic review and updated meta-analysis. *Eur J Epidemiol.* 2022;37(4):321. <https://doi.org/10.1007/S10654-022-00858-5>.
111. Yang J, Zhou J, Yang J, et al. Dark chocolate intake and cardiovascular diseases: a Mendelian randomization study. *Sci Rep.* 2024. <https://doi.org/10.1038/S41598-023-50351-6>.
112. Alkerwi A, Sauvageot N, Crichton GE, Elias MF, Stranges S. Daily chocolate consumption is inversely associated with insulin resistance and liver enzymes in the observation of cardiovascular risk factors in Luxembourg study. *Br J Nutr.* 2016;115(9):1661–8. <https://doi.org/10.1017/S0007114516000702>.
113. Laveriano-Santos EP, Arancibia-Riveros C, Tresserra-Rimbau A, et al. Flavonoid intake from cocoa-based products and adiposity parameters in adolescents in Spain. *Front Nutr.* 2022. <https://doi.org/10.3389/FNUT.2022.931171>.
114. Ren Y, Liu Y, Sun XZ, et al. Chocolate consumption and risk of cardiovascular diseases: a meta-analysis of prospective studies. *Heart.* 2019;105(1):49–55. <https://doi.org/10.1136/HEARTJNL-2018-313131>.
115. Morze J, Schwedhelm C, Bencic A, et al. Chocolate and risk of chronic disease: a systematic review and dose-response meta-analysis. *Eur J Nutr.* 2020;59(1):389–97. <https://doi.org/10.1007/S00394-019-01914-9/FIGURES/1>.
116. Veronese N, Demurtas J, Celotto S, et al. Is chocolate consumption associated with health outcomes? An umbrella review of systematic reviews and meta-analyses. *Clin Nutr.* 2019;38(3):1101–8. <https://doi.org/10.1016/j.clnu.2018.05.019>.
117. Frumuzachi O, Babotă M, Tanase C, Mocan A. A systematic review of randomized controlled trials on the health effects of chocolate enriched/fortified/supplemented with functional components. *Food Funct.* 2024;15(13):6883–99. <https://doi.org/10.1039/D4FO01574F>.
118. Fredholm BB, Bättig K, Holmén J, Nehlig J, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. *Pharmacol Rev.* 1999;51(1):83–133.
119. van Dam RM, Hu FB, Willett WC. Coffee, Caffeine, and Health. *N Engl J Med.* 2020;383(4):369–78. <https://doi.org/10.1056/nejma1816604>.
120. Paul O, Lepper MH, Phelan WH, Dupertuis GW, Macmillan A, Mckean H, Park H. A longitudinal study of coronary heart disease. *Circulation.* 1963;28(1):20–31. <https://doi.org/10.1161/01.CIR.28.1.20>.
121. Ding M, Bhupathiraju SN, Satija A, Van Dam RM, Hu FB. Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies. *Circulation.* 2014;129(6):643–59. <https://doi.org/10.1161/CIRCULATIONAHA.113.005925/DC1>.
122. Liu J, Sui X, Lavie CJ, et al. Association of coffee consumption with all-cause and cardiovascular disease mortality. *Mayo Clin Proc.* 2013;88(10):1066–74. <https://doi.org/10.1016/J.MAYOCP.2013.06.020>.
123. Lu X, Zhu X, Li G, et al. Habitual coffee, tea, and caffeine consumption, circulating metabolites, and the risk of cardiometabolic multimorbidity. *J Clin Endocrinol Metab.* 2024. <https://doi.org/10.1210/CLINEM/DGAE552>.
124. Kiyohara C, Kono S, Honjo S, et al. Inverse association between coffee drinking and serum uric acid concentrations in middle-aged Japanese males. *Br J Nutr.* 1999;82(2):125–30. <https://doi.org/10.1017/S0007114599001270>.
125. Zhang Y, Yang T, Zeng C, et al. Is coffee consumption associated with a lower risk of hyperuricaemia or gout? A systematic review and meta-analysis. *BMJ Open.* 2016. <https://doi.org/10.1136/BMJOPEN-2015-009809>.
126. Choi HK, Curhan G. Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. *Arthritis Rheum.* 2007;57(5):816–21. <https://doi.org/10.1002/ART.22762>.
127. Mezue K, Osborne MT, Abohashem S, et al. Reduced stress-related neural network activity mediates the effect of alcohol on cardiovascular risk. *J Am Coll Cardiol.* 2023;81(24):2315–25. <https://doi.org/10.1016/J.JACC.2023.04.015>.
128. Lee DI, Kim S, Kang DO. Exploring the complex interplay between alcohol consumption and cardiovascular health: mechanisms, evidence, and future directions. *Trends Cardiovasc Med.* 2025. <https://doi.org/10.1016/J.TCM.2024.12.011>.
129. Xi B, Veeranki SP, Zhao M, Ma C, Yan Y, Mi J. Relationship of alcohol consumption to all-cause, cardiovascular, and cancer-related mortality in US adults. *J Am Coll Cardiol.* 2017;70(8):913–22. <https://doi.org/10.1016/J.JACC.2017.06.054>.
130. Wood AM, Kaptoge S, Butterworth A, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. *Lancet.* 2018;391(10129):1513–23. [https://doi.org/10.1016/S0140-6736\(18\)30134-X](https://doi.org/10.1016/S0140-6736(18)30134-X).
131. Ge L, Sadeghirad B, Ball GDC, et al. Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials. *BMJ.* 2020. <https://doi.org/10.1136/BMJ.M696>.
132. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or

- nuts. *N Engl J Med*. 2018;378(25):1–14. <https://doi.org/10.1056/nejmoa1800389>.
133. Hernandez AV, Marti KM, Marti KE, et al. Effect of mediterranean diets on cardiovascular risk factors and disease in overweight and obese adults: a systematic review and meta-analysis of randomized controlled trials. *J Am Nutr Assoc*. 2025. <https://doi.org/10.1080/27697061.2024.2440051>.
134. Krebs JD, Parry-Strong A, Braakhuis A, et al. A Mediterranean dietary pattern intervention does not improve cardiometabolic risk but does improve quality of life and body composition in an Aotearoa New Zealand population at increased cardiometabolic risk: a randomised controlled trial. *Diabetes Obes Metab*. 2025. <https://doi.org/10.1111/DOM.16030>.
135. Casas R, Ruiz-León AM, Argente J, Alasvalar C, Bajoub A, Bertomeu I, Caroli M, Castro-Barquero S, Crispi F, Delarue J, Fernández-Jiménez R. A new mediterranean lifestyle pyramid for children and youth: a critical lifestyle tool for preventing obesity and associated cardiometabolic diseases in a sustainable context. *Adv Nutr*. 2025;16(3):100381. <https://doi.org/10.1016/J.ADVNUT.2025.100381>.
136. Schwingshackl L, Chaimani A, Hoffmann G, Schwedhelm C, Boeing H. A network meta-analysis on the comparative efficacy of different dietary approaches on glycaemic control in patients with type 2 diabetes mellitus. *Eur J Epidemiol*. 2018;33(2):157–70. <https://doi.org/10.1007/s10654-017-0352-x>.
137. Mente A, De Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. *Arch Intern Med*. 2009;169(7):659–69. <https://doi.org/10.1001/ARCHINTERNMED.2009.38>.
138. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH collaborative research group. *N Engl J Med*. 1997;336(16):1117–24. <https://doi.org/10.1056/NEJM199704173361601>.
139. Orlich MJ, Singh PN, Sabaté J, et al. Vegetarian dietary patterns and mortality in adventist health study 2. *JAMA Intern Med*. 2013;173(13):1230. <https://doi.org/10.1001/JAMAINTERNMED.2013.6473>.
140. Rizzo NS, Sabaté J, Jaceldo-Siegl K, Fraser GE. Vegetarian dietary patterns are associated with a lower risk of metabolic syndrome: the adventist health study 2. *Diabetes Care*. 2011;34(5):1225–7. <https://doi.org/10.2337/DC10-1221>.
141. Tonstad S, Butler T, Yan R, Fraser GE. Type of vegetarian diet, body weight, and prevalence of type 2 diabetes. *Diabetes Care*. 2009;32(5):791–6. <https://doi.org/10.2337/DC08-1886>.
142. Jenkins DJA, Jones PJH, Lamarche B, et al. Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial. *JAMA*. 2011;306(8):831–9. <https://doi.org/10.1001/JAMA.2011.1202>.
143. Chivaroli L, Nishi SK, Khan TA, et al. Portfolio dietary pattern and cardiovascular disease: a systematic review and meta-analysis of controlled trials. *Prog Cardiovasc Dis*. 2018;61(1):43–53. <https://doi.org/10.1016/J.PCAD.2018.05.004>.
144. Martins LB, Gamba M, Stubbendorff A, et al. Association between the EAT-lancet diet, incidence of cardiovascular events, and all-cause mortality: results from a swiss cohort. *J Nutr*. 2024. <https://doi.org/10.1016/J.TJNUT.2024.12.012>.
145. Satija A, Bhupathiraju SN, Spiegelman D, et al. Healthful and unhealthful plant-based diets and the risk of coronary heart disease in US adults. *J Am Coll Cardiol*. 2017;70(4):411–22. <https://doi.org/10.1016/J.JACC.2017.05.047>.
146. Schwingshackl L, Hoffmann G. Comparison of the long-term effects of high-fat v. low-fat diet consumption on cardiometabolic risk factors in subjects with abnormal glucose metabolism: a systematic review and meta-analysis. *Br J Nutr*. 2014;111(12):2047–58. <https://doi.org/10.1017/S0007114514000464>.
147. Kodama S, Saito K, Tanaka S, et al. Influence of fat and carbohydrate proportions on the metabolic profile in patients with type 2 diabetes: a meta-analysis. *Diabetes Care*. 2009;32(5):959–65. <https://doi.org/10.2337/DC08-1716>.
148. Crosby L, Davis B, Joshi S, et al. Ketogenic diets and chronic disease: weighing the benefits against the risks. *Front Nutr*. 2021;8: 702802. <https://doi.org/10.3389/FNUT.2021.702802/BIBTEX>.
149. Zhu H, Bi D, Zhang Y, et al. Ketogenic diet for human diseases: the underlying mechanisms and potential for clinical implementations. *Signal Transduct Target Ther*. 2022;7(1):1–21. <https://doi.org/10.1038/s41392-021-00831-w>.
150. Yuen AWC, Sander JW. Rationale for using intermittent calorie restriction as a dietary treatment for drug resistant epilepsy. *Epilepsy Behav*. 2014;33:110–4. <https://doi.org/10.1016/j.yebeh.2014.02.026>.
151. Westman EC, Tondt J, Maguire E, Yancy WS. Implementing a low-carbohydrate, ketogenic diet to manage type 2 diabetes mellitus. *Expert Rev Endocrinol Metab*. 2018;13(5):263–72. <https://doi.org/10.1080/17446651.2018.1523713>.
152. Hallberg SJ, McKenzie AL, Williams PT, et al. Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year: an open-label, non-randomized, Controlled Study Diabetes Ther. 2018;9(2):583–612. <https://doi.org/10.1007/S13300-018-0373-9/FIGURES/4>.
153. Tuccinardi D, Watanabe M, Masi D, et al. Rethinking weight loss treatments as cardiovascular medicine in obesity, a comprehensive review. *Eur J Prev Cardiol*. 2024. <https://doi.org/10.1093/EURJPC/ZWAE171>.
154. Kirkpatrick CF, Bolick JP, Kris-Etherton PM, et al. Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: a scientific statement from the national lipid association nutrition and lifestyle task force. *J Clin Lipidol*. 2019;13(5):689–711.e1. <https://doi.org/10.1016/J.JACL.2019.08.003>.
155. Hall KD, Guo J, Courville AB, et al. Effect of a plant-based, low-fat diet versus an animal-based, ketogenic diet on ad libitum energy intake. *Nat Med*. 2021;27(2):344–53. <https://doi.org/10.1038/S41591-020-01209-1>.
156. Eaton SB, Konner M. Paleolithic nutrition. *N Engl J Med*. 1985;312(5):283–9. <https://doi.org/10.1056/NEJM198501313120505>.
157. Eaton SB, Konner MJ, Cordain L. Diet-dependent acid load, Paleolithic nutrition, and evolutionary health promotion. *Am J Clin Nutr*. 2010;91(2):295–7. <https://doi.org/10.3945/AJCN.2009.29058>.
158. Manheimer EW, Van Zuuren EJ, Fedorowicz Z, Pijl H. Paleolithic nutrition for metabolic syndrome: systematic review and meta-analysis. *Am J Clin Nutr*. 2015;102(4):922–32. <https://doi.org/10.3945/AJCN.115.113613>.
159. Jamka M, Kulczyński B, Juruć A, Gramza-michałowska A, Stokes CS, Walkowiak J. The effect of the paleolithic diet vs. healthy diets on glucose and insulin homeostasis: a systematic review and meta-analysis of randomized controlled trials. *J Clin Med*. 2020;9(2):296. <https://doi.org/10.3390/JCM9020296>.
160. Fontana L, Partridge L, Longo VD. Dietary restriction, growth factors and aging: from yeast to humans. *Science*. 2010;328(5976):321. <https://doi.org/10.1126/SCIENCE.1172539>.
161. Di Francesco A, Deighan AG, Litichevskiy L, et al. Dietary restriction impacts health and lifespan of genetically diverse mice. *Nat*. 2024;634(8034):684–92. <https://doi.org/10.1038/s41586-024-08026-3>.
162. Anton SD, Moehl K, Donahoo WT, et al. Flipping the metabolic switch: understanding and applying the health benefits of fasting. *Obesity*. 2018;26(2):254–68. <https://doi.org/10.1002/OBY.22065>.
163. Ruppert PMM, Kersten S. Mechanisms of hepatic fatty acid oxidation and ketogenesis during fasting. *Trends Endocrinol Metab*. 2024;35(2):107–24. <https://doi.org/10.1016/J.TEM.2023.10.002/ASSET/9BE84CDA-6659-445B-9467-2A8F5161BF98/MAIN.ASSETS/GR2.JPG>.
164. Ezzati A, Tamargo JA, Golberg L, Haub MD, Anton SD. The effects of time-restricted eating on inflammation and oxidative stress in overweight older adults: a pilot study. *Nutr*. 2025;17(2):322. <https://doi.org/10.3390/NU17020322>.
165. Bosch-Sierra N, Grau-del Valle C, Salom C, et al. Effect of a very low-calorie diet on oxidative stress, inflammatory and metabolomic profile in metabolically healthy and unhealthy obese subjects. *Antioxidants*. 2024. <https://doi.org/10.3390/ANTIOX13030302>.
166. Ezzati A, McLaren C, Bohlman C, Tamargo JA, Lin Y, Anton SD. Does time-restricted eating add benefits to calorie restriction? A systematic review. *Obesity*. 2024;32(4):640–54. <https://doi.org/10.1002/oby.23984>.
167. Ezzati A, Rosenkranz SK, Phelan J, Logan C. The effects of isocaloric intermittent fasting vs daily caloric restriction on weight loss and metabolic risk factors for noncommunicable chronic diseases: a systematic review of randomized controlled or comparative trials. *J Acad Nutr Diet*. 2023;123(2):318–329. e1. <https://doi.org/10.1016/J.JAND.2022.09.013>.
168. Wilkinson MJ, Manoogian ENC, Zadourian A, et al. Ten-hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome. *Cell Metab*. 2020;31(1):92–104.e5. <https://doi.org/10.1016/J.CMET.2019.11.004>.
169. Schroder JD, Falqueto H, Mânica A, et al. Effects of time-restricted feeding in weight loss, metabolic syndrome and cardiovascular risk in obese women. *J Transl Med*. 2021;19(1):1–11. <https://doi.org/10.1186/S12967-020-02687-0/FIGURES/4>.
170. Rovira-Llopis S, Luna-Marco C, Perea-Galera L, Bañuls C, Morillas C, Victor VM. Circadian alignment of food intake and glycaemic control by time-restricted eating: a systematic review and meta-analysis. *Rev Endocr Metab Disord*. 2024;25(2):325–37. <https://doi.org/10.1007/S11154-023-09853-X>.



171. Liu J, Yi P, Liu F. The effect of early time-restricted eating vs later time-restricted eating on weight loss and metabolic health. *J Clin Endocrinol Metab*. 2023;108(7):1824–34. <https://doi.org/10.1210/CLINEM/DGAD036>.
172. Liang X, Chen J, An X, et al. The optimal time restricted eating interventions for blood pressure, weight, fat mass, glucose, and lipids: a meta-analysis and systematic review. *Trends Cardiovasc Med*. 2024;34(6):389–401. <https://doi.org/10.1016/J.TCM.2023.10.002>.
173. Liu D, Huang Y, Huang C, et al. Calorie restriction with or without time-restricted eating in weight loss. *N Engl J Med*. 2022;386(16):1495–504. [https://doi.org/10.1056/NEJMOA2114833/SUPPL\\_FILE/NEJMOA2114833\\_DATA-SHARING.PDF](https://doi.org/10.1056/NEJMOA2114833/SUPPL_FILE/NEJMOA2114833_DATA-SHARING.PDF).
174. Lowe DA, Wu N, Rohdin-Bibby L, et al. Effects of time-restricted eating on weight loss and other metabolic parameters in women and men with overweight and obesity: the TREAT randomized clinical trial. *JAMA Intern Med*. 2020;180(11):1491–9. <https://doi.org/10.1001/JAMAINTERNMED.2020.4153>.
175. Dote-Montero M, Clavero-Jimeno A, Merchán-Ramírez E, et al. Effects of early, late and self-selected time-restricted eating on visceral adipose tissue and cardiometabolic health in participants with overweight or obesity: a randomized controlled trial. *Nat Med*. 2025;31(2):524–33. <https://doi.org/10.1038/S41591-024-03375-Y>.
176. Cai H, Qin YL, Shi ZY, et al. Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial. *BMC Gastroenterol*. 2019;19(1):1–8. <https://doi.org/10.1186/S12876-019-1132-8/FIGURES/3>.
177. Sutton EF, Beyl R, Early KS, Cefalu WT, Ravussin E, Peterson CM. Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. *Cell Metab*. 2018;27(6):1212–1221.e3. <https://doi.org/10.1016/J.CMET.2018.04.010/ATTACHMENT/FBA3B141-BD8B-4DA2-8F4B-AA52D239BF90/MMC2.PDF>.
178. Stote KS, Baer DJ, Spears K, et al. A controlled trial of reduced meal frequency without caloric restriction in healthy, normal-weight, middle-aged adults. *Am J Clin Nutr*. 2007;85(4):981–8. <https://doi.org/10.1093/AJCN/85.4.981>.
179. Cienfuegos S, Gabel K, Kalam F, et al. Effects of 4- and 6-h time-restricted feeding on weight and cardiometabolic health: a randomized controlled trial in adults with obesity. *Cell Metab*. 2020;32(3):366–378.e3. <https://doi.org/10.1016/J.CMET.2020.06.018/ATTACHMENT/758FDB7F-91E3-4693-A74C-6E00EA129089/MMC2.PDF>.
180. Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. *Curr Opin Gastroenterol*. 2015;31(1):69. <https://doi.org/10.1097/MOG.0000000000000139>.
181. Ridaura VK, Faith JJ, Rey FE, et al. Cultured gut microbiota from twins discordant for obesity modulate adiposity and metabolic phenotypes in mice. *Science*. 2013. <https://doi.org/10.1126/SCIENCE.1241214>.
182. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology*. 2012;143(4):913–916.e7. <https://doi.org/10.1053/J.gastro.2012.06.031>.
183. Hibberd MC, Webber DM, Rodionov DA, et al. Bioactive glycans in a microbiome-directed food for children with malnutrition. *Nature*. 2024;625(7993):157–65. <https://doi.org/10.1038/s41586-023-06838-3>.
184. Chen RY, Mostafa I, Hibberd MC, et al. A microbiota-directed food intervention for undernourished Children. *N Engl J Med*. 2021;384(16):1517–28. <https://doi.org/10.1056/NEJMOA2023294>.
185. Gehrig JL, Venkatesh S, Chang HW, et al. Effects of microbiota-directed foods in gnotobiotic animals and undernourished children. *Science*. 2019. <https://doi.org/10.1126/SCIENCE.AAU4732>.
186. Koopen A, Witjes J, Wortelboer K, et al. Duodenal anaerobutyricum soehnge-nii infusion stimulates GLP-1 production, ameliorates glycaemic control and beneficially shapes the duodenal transcriptome in metabolic syndrome subjects: a randomised double-blind placebo-controlled cross-over study. *Gut*. 2022;71(8):1577–87. <https://doi.org/10.1136/gutjnl-2020-323297>.
187. Perraudeau F, McMurdie P, Bullard J, et al. Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation. *BMJ Open Diabetes Res Care*. 2020. <https://doi.org/10.1136/BMJDR-2020-001319>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.